Business Wire

NILEMDO ® Delivers Significant Cholesterol Lowering in Addition to Statin Therapy Which is Maintained During 2.5 Years of Treatment

Share

Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced that NILEMDO® (bempedoic acid) has demonstrated consistent tolerability and sustained efficacy over 2.5 years, in results presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology. Bempedoic acidis approved in Europe to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hypercholesterolaemia or mixed dyslipidaemia.1 Up to 80% of patients do not reach guideline-recommended LDL-C goals despite receiving treatments such as statins and other lipid-lowering therapies (LLTs), and are at increased risk of a heart attack or stroke.3,4,5

The data presented at ESC Congress 2020 comes from an open-label extension of the CLEAR Harmony trial, which originally showed that bempedoic acidis generally well tolerated and significantly reduces LDL-C compared to placebo at 12 weeks, on top of statins and other oral LLTs. This was maintained over the 52 weeks of the trial.6 People who completed CLEAR Harmony had the option to be enrolled into the open-label extension in which all participants received bempedoic acid for an additional 78 weeks, meaning some patients received treatment for 130 weeks in total. Findings from the extension study showed that bempedoic acid significantly lowered LDL-C by 14.4% on top of maximally tolerated statin therapy and other LLTs throughout 78 weeks of treatment, which are consistent with results seen in the original study.7

“Many people have a long-term need for treatments that are well tolerated and will help them keep their LDL-C levels low in order to reduce their risk of cardiovascular events, such as a heart attack or stroke. Therefore, it is important to know how people respond to treatment over longer-term time periods,” said Professor Kausik Ray, Professor of Public Health, Director of the Imperial Centre for CVD Prevention, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials Imperial College London and Consultant Cardiologist. “This study can give our colleagues confidence that the LDL-C reductions we see with bempedoic acid are maintained over time, without a significant increase of overall adverse events on top of statins and other LLTs.”

“Patients enrolled in CLEAR Harmony required additional LDL-C lowering, despite receiving maximum tolerated statin therapy and other oral LLTs. This is a group of people who are at high cardiovascular risk and have a significant need for combination therapies that can reduce cholesterol further,” said Dr. Michael Kerschnitzki, Medical Affairs Director, Antithrombotic & Cardiovascular at Daiichi Sankyo Europe. “Bempedoic acidand the bempedoic acid / ezetimibe fixed-dose combination tablet act in a complementary manner to existing LLTs and could become important additional treatments for patients to reach their LDL-C goals.”

This year’s ESC Congress 2020 is a virtual experience being held online due to travel restrictions. For more information please visit https://www.escardio.org/Congresses-&-Events/ESC-Congress.

– ENDS –

About NILEMDO®

NILEMDO® (bempedoic acid) is a new, first-in-class, oral treatment which lowers cholesterol, and which can be combined with other oral treatments to help lower cholesterol even further.1 Bempedoic acid inhibits ATP citrate lyase (ACL), an enzyme which is involved in the production of cholesterol in the liver.1

NILEMDO® has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:1

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

NILEMDO® acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to statin or other lipid-lowering therapies.1 Due to its unique mechanism of action, NILEMDO® is not activated in skeletal muscle.1

About NUSTENDI®

NUSTENDI® is a new oral treatment which combines two complementary ways of reducing cholesterol in a convenient once-daily tablet. NUSTENDI® is a fixed dose combination tablet containing bempedoic acid (the active pharmaceutical ingredient in NILEMDO®) and ezetimibe.8

NUSTENDI® has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:8

  • in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe,
  • alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,
  • in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without a statin.

Daiichi Sankyo Europe has licensed exclusive commercialisation rights to NILEMDO® and NUSTENDI® in the European Economic Area, Turkey and Switzerland from Esperion and is the full Marketing Authorisation Holder in these territories.

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centred around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.

1 European Medicines Agency. NILEMDO® Summary of Product Characteristics. March 2020.
2 Pinkosky SL, et al. Liver- specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature Communications. 2016; 7:13457. DOI:10.1038/ncomms13457.
3 The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemia. Eur Heart J. 2020 Jan 1;41(1):111-188. doi:10.1093/eurheartj/ehz455.
4 Fox KM, et al. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol 2018; 107: 380–388.
5 Kotseva K, et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardio. 2019;26(8):824–835.
6 Ray KK, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019; 380:1022–32
7 Ballantyne CM, et al. Long-term safety and efficacy of bempedoic acid in patients at high risk of atherosclerotic cardiovascular disease: results from the clear harmony open-label extension. Poster presentation at the European Society of Cardiology Congress 2020.
8 European Medicines Agency. NUSTENDI® Summary of Product Characteristics. March 2020.

Contact information

Dr. Wolfgang Schiessl (Europe)
Daiichi Sankyo Europe GmbH
Director Product PR and Communications, Cardiovascular Europe
+49 151 1714 7317

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rimini Street Celebrates 15 Years of Delivering Client Success28.9.2020 15:00:00 CESTPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of business software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that September marks the 15th anniversary of the Company’s founding in 2005 to redefine the enterprise software support market. The Company set out to deliver a premium, ultra-responsive support model, and bring choice and value to software licensees around the world. Since its inception, Rimini Street has continually set the premium standard on what Oracle and SAP licensees should expect from their support experience. The Company is responsible for delivering a long history of innovative “firsts” for the enterprise software support market, including guaranteed ultra-responsive SLA’s, support for customizations at no additional cost, support for at least 15 years without required upgrades or updates and saving clients nearly $5 billion in total maintenance and support cos

Epic Fantasy 3DMMORPG Forsaken World: Gods and Demons Open for Pre-registration Today28.9.2020 15:00:00 CESTPress release

Forsaken World: Gods and Demons is an open-world fantasy MMORPG on an incredible scale. Dive into a world of never-ending adventure where treasure and glory awaits the victor. Raid a dragon's lair, search for lost artifacts, or kick back, relax and catch some fish in between epic adventures. The world around you will be influenced by your in-game decisions, with a storyline that allows you to determine the future of Calindor. Leave your mark and become a legend! This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200928005293/en/ Pre-register now on the App Store and Google Play (Graphic: Business Wire) Endless Character Customization Change your class at any time and specialize your character just the way you want it. Mix and match abilities and talents to fit your combat style, and customize your appearance to bring out the true you, right down to the facial expression. No two players are the same in FW: GD. A Stunning World Im

Hyprevention Raises New Financing to Commercialize Spinal Implant Product V-STRUT© in the USA.28.9.2020 14:55:00 CESTPress release

Hyprevention has raised new financing to support the V-STRUT© Vertebral Implant product. The financing will be used to execute the commercialization plans for the US spinal fracture market. The V-STRUT© Vertebral Implant is indicated for use in the treatment of vertebral fractures. In May 2019, a US patent was granted for V-STRUT© and in March 2020, the device received FDA-510(k) clearance. “We are delighted that our existing investors have shown confidence in our product development efforts and commercialization plans for the US market by increasing their investment in the company,” says Cecile Vienney, CEO. The Hyprevention team has entered into a commercial relationship with DAWA Medical and has received several orders for the product from enthusiastic customers. DAWA Medical, a regional distributor of medical products, will promote sales in Florida, Illinois, Texas and Oklahoma. In addition to DAWA the company is in discussion with other commercial partners to bring the innovative

Mavenir acquires ip.access to expand OpenRAN radio portfolio for CSPs and Enterprise Private Networks28.9.2020 14:00:00 CESTPress release

Mavenir, a leading provider of end-to-end cloud-native Network Software Provider for Communications Service Providers (CSPs) announces today that it has acquired ip.access Ltd, a leading 2G, 3G, 4G and 5G-ready small cell solutions provider. This acquisition extends Mavenir’s leadership in OpenRAN radio on three fronts: Communication Service Providers: Adding 2G and 3G capabilities to the OpenRAN portfolio Enterprise: Adding a full suite of enterprise radio solutions for Mavenir’s Private Network offerings, including OnGo/CBRS certified solutions Nontraditional Networks: Leveraging market leading software defined vRAN solutions for Aviation, Maritime, Rural and Remote networks with next generation solutions in the air, on land and at sea. “Operators are looking to transform their 2G/3G networks as they migrate to 4G and 5G,” said Pardeep Kohli, President and CEO, Mavenir. “We expect to provide a seamless, multi radio access technology single RAN offering for those operators that allows

PCI Pharma Services Introduces First-of-its-Kind Digital Platform to Provide Clients with Real-Time Supply Chain Data and Analytics28.9.2020 12:00:00 CESTPress release

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider today announced the launch of pci | bridge, an innovative digital platform that will give customers immediate visibility into their clinical and commercial supply chain, and provide instantaneous data and insights to inform decision-making. Created using an agile development process whereby key clients collaborated and provided input, PCI built an industry-leading digital interface that delivers greater transparency to clients – saving time and resources to ultimately help bring life-changing therapies to patients faster. The launch of pci | bridge is one of many initiatives that PCI has undertaken to incorporate digital transformation as core to its business strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200928005059/en/ pci | bridge digital platform logo (Photo: Business Wire) “At PCI, we are always loo

MILAN AIRPORTS MALPENSA & LINATE FIRST IN ITALY TO DEPLOY ECAC STANDARD 3 CABIN BAGGAGE SCREENING SYSTEMS WITH SMITHS DETECTION28.9.2020 11:00:00 CESTPress release

Smiths Detection today announced that it has been awarded a contract by SEA Group to support the upgrade of Malpensa and Linate Airports, two of the three international airports in Milan, to the highest security standard for cabin baggage in the industry - ECAC EDS CB C3. As part of the implementation, up to 18 advanced Computed Tomography (CT) screening systems — HI-SCAN 6040 CTiX — will be installed at Milano Malpensa Airport Terminal 1 along with up to 10 more at Milano Linate Airport. Besides providing advanced explosives detection with low false alarm rates, the CT technology allows electronic devices and liquids to remain in bags. SEA Group also selected Smiths Detection’s HI-SCAN 6040 CTiX carry-on baggage scanners to help protect the health of travellers by reducing the number of trays required during security screening and minimising points of contact at security lanes. “As key gateways to the rest of the world for Milan, our priority for Malpensa and Linate airports is to pro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom